Actavis receives approval for Bupropion Hydrochloride tablets

Actavis has received two separate approvals from the USFDA to market Bupropion Hydrochloride extended-release tablets. Distribution of the products will commence immediately. Bupropion Hydrochloride extended-release tablets, available in 150mg strength, are the generic equivalent of Wellbutrin and are indicated for the treatment of major depressive disorder. Annual sales of brand and generic Wellbutrin were US $498 million for the 12 months ending December 2007 according to IMS Health data.